1 min read
Add as a preferred source on Google

Biohaven Plans Pivotal Trial for Cancer Candidate BHV-1530 by 2027

The company announced early-stage trial data for the antibody-drug conjugate on Nov. 19.

A laboratory vial stands beside a sealed sample tube / TokenPost.ai
A laboratory vial stands beside a sealed sample tube / TokenPost.ai

Biohaven Ltd. (BHVN) shares rose Nov. 19 after the company announced early-stage trial data for cancer candidate BHV-1530 and plans to advance it to a pivotal trial as early as 2027.

BHV-1530 is an antibody-drug conjugate.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…